NCT03454581

Brief Summary

The aim of the present study was to investigate the effect of photobiomodulation (PBM) and manual therapy (MT) isolated or combined in the reduce of pain, the improve of mandibular movements, the psychosocial aspects and the anxiety symptoms of patients with TMD.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
51

participants targeted

Target at P25-P50 for phase_2

Timeline
Completed

Started May 2016

Shorter than P25 for phase_2

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 17, 2016

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 14, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 14, 2016

Completed
1.2 years until next milestone

First Submitted

Initial submission to the registry

February 5, 2018

Completed
29 days until next milestone

First Posted

Study publicly available on registry

March 6, 2018

Completed
1.6 years until next milestone

Results Posted

Study results publicly available

September 26, 2019

Completed
Last Updated

September 26, 2019

Status Verified

August 1, 2019

Enrollment Period

6 months

First QC Date

February 5, 2018

Results QC Date

March 10, 2018

Last Update Submit

August 26, 2019

Conditions

Keywords

Temporomandibular DiseasesPhotobiomodulationLow level laserTreatmentManual Therapy

Outcome Measures

Primary Outcomes (1)

  • Change From Baseline in Visual Analogic Scale (VAS) for Pain

    Visual Analogic Score (VAS) is a psychometric scale used to measure subjective characteristics, as pain. Consists of a 100mm horizontal line with descriptors "no pain" at the initial point (score 0) and "worst pain" at the end point (score 100). To avoid clustering of scores, numbers or verbal descriptors at intermediate points are not recommended. Patients were asked to place a handwritten mark at one point along the 100mm line that best represents their pain intensity. The scores are recorded in millimeters and determined by the measurements from the initial point of the scale to the patients' mark, using a ruler. Higher scores indicate high levels of pain intensity. In this study, the scores (mm) of pain were recorded at days 7, 14, 21, 28, 60 and 90 and compared to the baseline score (day 0) to evaluate the response to each treatment.

    0,7,14,21,28,60,90 days

Secondary Outcomes (7)

  • Change at Jaw Movements

    0,28,90 days

  • Change on Chronic Pain Grades

    0,90 days

  • Changes on Levels of Depression Symptoms

    0,90 days

  • Change on Nonspecific Physical Symptoms With Pain

    0, 90 days

  • Change on Nonspecific Physical Symptoms Without Pain

    0, 90 days

  • +2 more secondary outcomes

Study Arms (3)

Photobiomodulation group (PBM)

EXPERIMENTAL

Gallium-aluminium-arsenide (GaAlAs) diode laser (MM Optics Recover, São Carlos, São Paulo, Brazil) with a wavelength of 808 nm, punctual contact mode,spot size of 0.03 cm2, power output of 100 mW, output density of 333 mW∕cm2, energy density of 13.3 J ∕cm2, 40 s exposure time per point, and 4 Joules (J) of total energy per point. 18 individuals

Procedure: Photobiomodulation

Manual Therapy group (MT)

EXPERIMENTAL

At masticatory muscles were performed circular movements, slip and compression with fingers movements. At the temporomandibular joint (TMJ) was performed a caudal distraction with anterior projection, placing the thumb on the second or third molar. 16 individuals.

Procedure: Manual Therapy (MT)

Combined therapy group (CT)

EXPERIMENTAL

Applied the protocols of PBM group and immediately after, to MT group. 17 individuals.

Procedure: PhotobiomodulationProcedure: Manual Therapy (MT)

Interventions

PBM was applied, three times a week for four consecutive weeks at 5 points in the TMJ region: superior, anterior, lateral, posterior and postero inferior to the condyle. In addition, all patients received laser application in the temporal muscle (anterior, middle and posterior), in the masseter (upper, middle and lower portion) and insertion of the medial pterygoid.

Also known as: Low Level Laser (PBM)
Combined therapy group (CT)Photobiomodulation group (PBM)

Patients were submitted to MT at temporal, masseter and pterygoid medial from both sides, during 3 minutes each muscle group (Extraoral) and at masseter and lateral pterygoid (Intraoral) for 3 minutes, each total 21 minutes. MT on the TMJ region was performed for 1 minute and 3 repetitions during three times a week .

Combined therapy group (CT)Manual Therapy group (MT)

Eligibility Criteria

Age21 Years+
Sexall(Gender-based eligibility)
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • TMD myogenic and arthrogenic diagnosis based in RDC/TMD Axis I analysis
  • Pain in temporomandibular joint (TMJ)
  • Limitation in mouth opening.

You may not qualify if:

  • Current dental or physical treatment
  • Polyarthritis and other rheumatic diseases
  • Use of anti-inflammatory and muscle relaxant

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Temporomandibular Joint Disorders

Interventions

Low-Level Light TherapyphytobacteriomycinMusculoskeletal Manipulations

Condition Hierarchy (Ancestors)

Craniomandibular DisordersMandibular DiseasesJaw DiseasesMusculoskeletal DiseasesJoint DiseasesMuscular DiseasesStomatognathic Diseases

Intervention Hierarchy (Ancestors)

Laser TherapyTherapeuticsPhototherapyComplementary TherapiesPhysical Therapy ModalitiesRehabilitation

Results Point of Contact

Title
PhD Manoela Domingues Martins
Organization
Federal University of Rio Grande do Sul

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

February 5, 2018

First Posted

March 6, 2018

Study Start

May 17, 2016

Primary Completion

November 14, 2016

Study Completion

November 14, 2016

Last Updated

September 26, 2019

Results First Posted

September 26, 2019

Record last verified: 2019-08